Metabolic Insights for APPs

The Metabolic Advanced Practice Providers (MAPP) is the first association solely focused on Advanced Practice Providers (APPs) working with metabolic conditions. MAPP provides a unique opportunity for nurse practitioners and physician assistants to join under one membership to work towards a common goal of excellence in metabolic medicine. MAPP recognizes the gaps in the standards of education and training of advanced practice providers who choose to work with metabolic conditions. Our goal is to create a home for metabolic APPs and offer educational resources to fill in these gaps by providing fellowship and certification opportunities.

Metabolic Insights for APPs is a health podcast hosted by MAPP, with 11 episodes on record and a Required Pod Score of 80.

MAPP hosts Metabolic Insights for APPs, a health show with 11 episodes published.

Our AI reads these to draft pitches. Use them as grounding for a pitch that cites a real guest and a specific topic.

• 

  Metabolic Insights for APPs

  Podcast: Fibrosis—Not Steatosis—Is the True Prognostic Driver in MASLD and MASH

  Mar 16, 202616 minS0

  <p>Thank you to Madrigal for sponsoring this podcast episode.</p><p>This educational discussion explores why fibrosis—not steatosis—is the key prognostic driver in metabolic dysfunction–associated steatotic liver disease (MASLD) and metabolic dysfunction–associated steatohepatitis (MASH). Physician assistants Kelsey Gaid, PA-C from the University of Utah Health and Andrew Garza, MPAS, PA-C review how fibrosis stage predicts liver-related outcomes, including progression to cirrhosis and hepatocellular carcinoma. The conversation highlights the importance of non-invasive assessment tools such as FibroScan, the role of patient education, and why identifying fibrosis early is critical for risk stratification and management.</p><p>The disc...

  ListenShow Notes
• 

  Metabolic Insights for APPs

  Medication Review: Prescribing in Practice: Safety, Monitoring, and Drug-Drug Interactions For Resmetirom

  Mar 16, 20264 minS0

  <p>Thank you to Madrigal for sponsoring this Medication Review Video Module.</p><p>In this educational video, Andrew Garza, MPAS, PA-C, provides a comprehensive clinical overview of safety monitoring, adverse events, and drug–drug interactions associated with Resmetirom, the first FDA-approved therapy for metabolic dysfunction–associated steatohepatitis (MASH) with F2–F3 fibrosis. Drawing from both clinical experience and data from the MAESTRO-NASH trial, Andrew reviews the most common side effects observed with resmetirom, including diarrhea, nausea, pruritus, vomiting, constipation, abdominal pain, and dizziness. He explains that gastrointestinal symptoms—particularly diarrhea and nausea—are the most frequent causes of discontinuation, though the...

  ListenShow Notes
• 

  Metabolic Insights for APPs

  FAQ: How Do You Decide What Testing To Do When Screening Patients For Hypercortisolism?

  Mar 16, 20265 minS0

  <p>Thank you to Corcept for sponsoring this FAQ Video Module. </p><p>In this educational endocrinology update, Amy Burmesh, PA-C, from the Medical College of Wisconsin shares a practical, step-by-step approach to screening for hypercortisolism and Cushing syndrome in clinical practice. She reviews the three primary screening tests for cortisol excess: the 24-hour urine free cortisol, late-night salivary cortisol (two samples), and the 1 mg overnight dexamethasone suppression test. The discussion highlights the strengths and limitations of each test, including sensitivity and specificity, patient compliance challenges, and when each option is most appropriate. Learn why the dexamethasone suppression test offers...

  ListenShow Notes
• 

  Metabolic Insights for APPs

  Medication Review: Mechanism of Action: The First Liver-Directed Thyroid Hormone Agonist

  Mar 16, 20263 minS0

  <p>Thank you to Madrigal for sponsoring this Medication Review Video Module.</p><p>In this video, Jessica Bartholomew, MSN, APRN, FNP-C, reviews the mechanism of action of resmetirom, the first FDA-approved liver-directed therapy for non-cirrhotic metabolic dysfunction–associated steatohepatitis (MASH) in patients with stage F2–F3 fibrosis. The discussion explains how selective activation of thyroid hormone receptor beta in the liver targets impaired hepatic lipid metabolism seen in MASH, helping reduce liver fat, inflammation, and fibrosis progression while minimizing systemic thyroid effects. Clinical outcomes from the MAESTRO-NASH trial and the significance of FDA accelerated approval are also reviewed, highlighting a ne...

  ListenShow Notes
• 

  Metabolic Insights for APPs

  FAQ: Statins & MASH: How Manageable Is The Interaction?

  Mar 16, 20263 minS0

  <p>Thank you to Madrigal for sponsoring this FAQ Video Module.</p><p>In this episode, Tammy Harper, NP-C, a transplant hepatology nurse practitioner at Keck Medicine of USC, shares real-world insights on managing statin therapy in patients with MASH and MASLD. Drawing from extensive experience in internal medicine and liver transplantation, she discusses when statins can be safely continued in cirrhosis, when dose adjustments may be appropriate, and how to monitor patients with compromised liver and kidney function. The discussion highlights collaboration with cardiology, practical lab monitoring strategies, and considerations before and after liver transplant, offering valuable guidance for...

  ListenShow Notes

Recent guests on Metabolic Insights for APPs. Study who booked and why before you pitch.

Based on semantic analysis of episode topics and host coverage, this show is a strong guest fit for executives in:

Industry fit is computed by PitchCentric using vector embeddings of the show's episode catalog.